We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis.
- Authors
Greuter, Thomas; Vavricka, Stephan R.; Biedermann, Luc; Pilz, Julia; Borovicka, Jan; Seibold, Frank; Sauter, Bernhard; Rogler, Gerhard
- Abstract
<bold><italic>Background:</italic></bold> Data on the efficacy of intercellular adhesion molecule-1 antisense oligonucleotide alicaforsen in ulcerative colitis (UC) is inconsistent. <bold><italic>Methods:</italic></bold> All patients, who had received at least one dose of alicaforsen, were analyzed retrospectively. Alicaforsen’s efficacy was assessed in patients treated for left-sided UC and proctitis by comparing clinical and (if applicable) endoscopic disease activity before/after treatment. <bold><italic>Results:</italic></bold> Twelve patients were treated for left-sided UC or proctitis. Eleven patients received a 6-week course of a once-daily 240 mg alicaforsen enema formulation. In 1 patient, treatment was discontinued, because it was found to be inefficient. Disease activity measured by the partial Mayo score and 6-point symptom score was significantly reduced after treatment (6.0 vs. 2.4, <italic>p</italic> = 0.011 and 3.7 vs. 1.4, <italic>p</italic> = 0.008). Faecal calprotectin showed a trend towards reduction (484.4 vs. 179.5 μg/g, <italic>p</italic> = 0.063). Clinical improvement was achieved in 10 patients (83.3%). In 7 patients, a relapse occurred (70%). Median duration of clinical improvement was 18.0 weeks (range 1–112). Three patients showed an ongoing improvement of >9 months. No adverse events were reported. <bold><italic>Conclusions:</italic></bold> A 6-week course of alicaforsen seemed to be safe and efficacious in inducing clinical improvement in patients with left-sided UC and proctitis. Prolonged clinical improvement was observed in many but not all patients.
- Subjects
ULCERATIVE colitis; COLITIS treatment; PROCTITIS; ANTISENSE nucleic acids; DRUG efficacy; DISEASE relapse; CELL adhesion molecules; THERAPEUTICS
- Publication
Digestive Diseases, 2018, Vol 36, Issue 2, p123
- ISSN
0257-2753
- Publication type
Article
- DOI
10.1159/000484979